Armistice Capital, LLC holds a diversified book of 251 stocks worth $3.0B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Unitedhealth Group Inc and trimmed PTC Therapeutics Inc. Their largest long position is Travere Therapeutics Inc at 5% of the equity book. They also disclosed $2.2B in put options (a bearish bet) and $347.8M in call options (bullish), shown separately below and excluded from the equity book. Cloning the disclosed picks since 2015 would be +347% (+13.9%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1601086/holdings"
Use Arkolith to show ARMISTICE CAPITAL, LLC's latest holdings, largest changes, and filing provenance.
The reported book (valued from quarter-end) returned +366.7%, a 20.1-point gap that is the cost of the ~45-day 13F disclosure lag a real follower can't avoid.
Growth of $10,000 cloning Armistice Capital, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~45 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Armistice Capital, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 80 / 80 | $1.1T |
| STATE STREET CORP | 80 / 80 | $551.0B |
| MORGAN STANLEY | 80 / 80 | $235.4B |
| GOLDMAN SACHS GROUP INC | 80 / 80 | $114.2B |
| UBS Group AG | 80 / 80 | $60.7B |
| WELLS FARGO & COMPANY/MN | 80 / 80 | $49.7B |
| BARCLAYS PLC | 80 / 80 | $47.3B |
| BNP PARIBAS FINANCIAL MARKETS | 80 / 80 | $22.3B |
Ranked by how many of Armistice Capital, LLC's top 80 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Travere Therapeutics Inc COM | $145.5M | 4.90M | 4.8% | ▲+30% Added · +1.1M sh | |
| 2 | PTC Therapeutics Inc COM | $141.3M | 2.07M | 4.7% | ▼−26% Reduced · −727K sh | |
| 3 | Madrigal Pharmaceuticals Inc COM | $138.5M | 264.6K | 4.6% | ▼−0.4% Reduced · −1K sh | |
| 4 | Supernus Pharmaceuticals COM | $98.0M | 1.90M | 3.2% | ▼−31% Reduced · −869K sh | |
| 5 | Neurocrine Biosciences Inc COM | $95.4M | 724.0K | 3.1% | ▼−12% Reduced · −96K sh | |
| 6 | Agios Pharmaceuticals Inc COM | $91.9M | 2.72M | 3.0% | ▼−11% Reduced · −320K sh | |
| 7 | Immunovant Inc COM | $88.6M | 3.56M | 2.9% | ▼−38% Reduced · −2.2M sh | |
| 8 | Freshpet Inc COM | $64.5M | 1.09M | 2.1% | ▼−16% Reduced · −203K sh | |
| 9 | Incyte Corp COM | $61.8M | 656.8K | 2.0% | ▼−40% Reduced · −441K sh | |
| 10 | Dyne Therapeutics Inc COM | $57.6M | 3.18M | 1.9% | ▼−2.3% Reduced · −75K sh | |
| 11 | Amazon Com Inc COM | $54.6M | 262.1K | 1.8% | ▼−29% Reduced · −105K sh | |
| 12 | Ironwood Pharmaceuticals Inc COM CL A | $52.7M | 15.03M | 1.7% | ▼−6.2% Reduced · −997K sh | |
| 13 | Cytokinetics Inc COM NEW | $50.4M | 764.5K | 1.7% | ▼−23% Reduced · −228K sh | |
| 14 | Harmony Biosciences Hldgs In COM | $45.5M | 1.62M | 1.5% | ▲+225% Added · +1.1M sh | |
| 15 | Thermo Fisher Scientific Inc COM | $45.0M | 91.5K | 1.5% | ▲+46% Added · +29K sh | |
| 16 | Nektar Therapeutics COM NEW | $41.6M | 578.0K | 1.4% | ▼−3.0% Reduced · −18K sh | |
| 17 | Unitedhealth Group Inc COM | $40.0M | 148.0K | 1.3% | ▲New New position | |
| 18 | Uber Technologies Inc COM | $37.3M | 518.8K | 1.2% | ▲+83% Added · +236K sh | |
| 19 | Immunocore Hldgs PLC ADS | $35.8M | 1.19M | 1.2% | ▲+8.2% Added · +90K sh | |
| 20 | Dentsply Sirona Inc COM | $34.8M | 3.00M | 1.1% | ▼−59% Reduced · −4.3M sh | |
| 21 | Rigel Pharmaceuticals Inc COM | $34.6M | 1.28M | 1.1% | ▲+53% Added · +444K sh | |
| 22 | Disc Medicine Inc COM | $34.3M | 536.0K | 1.1% | ▲+7.3% Added · +37K sh | |
| 23 | Alphabet Inc CAP STK CL A | $34.1M | 118.5K | 1.1% | ▼−40% Reduced · −78K sh | |
| 24 | Mineralys Therapeutics Inc COM | $31.9M | 1.18M | 1.1% | ▲+74% Added · +500K sh | |
| 25 | Hubspot Inc COM | $31.4M | 128.6K | 1.0% | ▲+89% Added · +61K sh | |
| 26 | Axogen Inc COM | $31.0M | 936.0K | 1.0% | —Held | |
| 27 | Orthofix Med Inc COM | $31.0M | 2.70M | 1.0% | ▲+2.0% Added · +52K sh | |
| 28 | Kura Oncology Inc COM | $30.4M | 3.74M | 1.0% | ▼−24% Reduced · −1.2M sh | |
| 29 | Avanos Med Inc COM | $28.0M | 2.00M | 0.9% | ▼−38% Reduced · −1.2M sh | |
| 30 | Regeneron Pharmaceuticals COM | $27.9M | 36.1K | 0.9% | ▼−57% Reduced · −48K sh | |
| 31 | Align Technology Inc COM | $27.1M | 158.0K | 0.9% | ▲+108% Added · +82K sh | |
| 32 | Mongodb Inc CL A | $26.3M | 107.3K | 0.9% | ▲+118% Added · +58K sh | |
| 33 | Alibaba Group Hldg Ltd SPONSORED ADS | $25.6M | 204.0K | 0.8% | ▼−36% Reduced · −115K sh | |
| 34 | Medline Inc COM CL A | $25.1M | 564.9K | 0.8% | ▲+874% Added · +507K sh | |
| 35 | Kalvista Pharmaceuticals Inc COM | $24.9M | 1.24M | 0.8% | ▲+55% Added · +436K sh | |
| 36 | Datadog Inc CL A COM | $24.6M | 208.6K | 0.8% | ▼−15% Reduced · −36K sh | |
| 37 | Humana Inc COM | $24.5M | 141.3K | 0.8% | ▲+97% Added · +70K sh | |
| 38 | Sentinelone Inc CL A | $24.4M | 1.90M | 0.8% | ▼−22% Reduced · −524K sh | |
| 39 | Verastem Inc COM NEW | $24.3M | 4.59M | 0.8% | ▲+30% Added · +1.1M sh | |
| 40 | Five9 Inc COM | $24.2M | 1.59M | 0.8% | ▼−20% Reduced · −408K sh | |
| 41 | Intuitive Surgical Inc COM NEW | $24.0M | 52.0K | 0.8% | ▼−15% Reduced · −9K sh | |
| 42 | Grifols S A SP ADR REP B NVT | $24.0M | 2.99M | 0.8% | ▲+7.9% Added · +220K sh | |
| 43 | Penn Entertainment Inc COM | $23.7M | 1.58M | 0.8% | ▼−49% Reduced · −1.5M sh | |
| 44 | Solid Biosciences Inc COM NEW | $23.0M | 3.20M | 0.8% | ▲+23% Added · +588K sh | |
| 45 | Gitlab Inc CLASS A COM | $22.3M | 1.03M | 0.7% | ▲+20% Added · +170K sh | |
| 46 | Autolus Therapeutics Ltd SPON ADS | $21.8M | 15.80M | 0.7% | ▼−9.7% Reduced · −1.7M sh | |
| 47 | Angiodynamics Inc COM | $21.3M | 1.87M | 0.7% | ▲+9.9% Added · +169K sh | |
| 48 | Arvinas Inc COM | $21.0M | 1.98M | 0.7% | ▲+9.9% Added · +178K sh | |
| 49 | Taiwan Semiconductor Manufac SPONSORED ADS | $20.7M | 61.3K | 0.7% | ▲+23% Added · +11K sh | |
| 50 | Alto Neuroscience Inc COM SHS | $20.5M | 912.0K | 0.7% | ▼−41% Reduced · −624K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P 500 ETF TRUST-USSPY | $1.4B | 2.1M |
| PUT · bearish | ISHARES RUSSELL 2000 ETFIWM | $868.0M | 3.5M |
| CALL · bullish | CYTOKINETICS INCCYTK | $112.0M | 1.7M |
| CALL · bullish | AGIOS PHARMACEUTICALS INCAGIO | $108.3M | 3.2M |
| CALL · bullish | IMMUNOVANT INCIMVT | $47.2M | 1.9M |
| CALL · bullish | PTC THERAPEUTICS INCPTCT | $26.6M | 390K |
| CALL · bullish | SENTINELONE INC -CLASS AS | $21.3M | 1.6M |
| CALL · bullish | FIVE9 INCFIVN | $19.0M | 1.3M |
| CALL · bullish | PENN ENTERTAINMENT INCPENN | $13.5M | 900K |
| PUT · bearish | CYTOKINETICS INCCYTK | $13.2M | 200K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 267 | $5.6B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 370 | $8.4B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 17, 2025 | 332 | $6.7B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 210 | $5.8B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 230 | $6.7B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 232 | $7.3B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 259 | $6.3B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 254 | $7.9B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 337 | $7.5B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 13, 2024 | 297 | $7.3B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 254 | $6.5B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 222 | $6.9B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 226 | $6.9B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 193 | $5.7B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 197 | $5.8B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 176 | $5.7B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 141 | $5.2B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 145 | $6.1B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 139 | $5.9B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 116 | $5.6B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 111 | $4.4B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Mar 4, 2021 | 106 | $2.2B | 13F-HR/A |
| Q3 2020 | Sep 30, 2020 | Nov 16, 2020 | 101 | $2.8B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.